Beyond the Scale: The Ozempic Effect
Episode 4: Off-Label Use and Compounded GLP-1 Drugs
10 Jul 2025
In Episode 4 of Beyond the Scale: The Ozempic Effect, hosts Terry Turner and Christian Simmons investigate the growing off-label use of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro — especially among people without diabetes. As demand surges, so does the use of cheaper, unregulated compounded versions sold through telehealth and med spas. Metabolic health expert Dr. Matt Chalmers explains who should — and shouldn’t — be taking these powerful medications. Clinical pharmacist Dr. Elizabeth Van Dril breaks down what off-label prescribing really means and when it can be dangerous. Rob Andrews, former Congressman and now CEO of the Health Transformation Alliance, raises alarms about the FDA’s limited oversight of compounding pharmacies. With stricter federal rules now in place, are patients any safer? And what risks still remain? This episode explores how access can outpace oversight — and why that’s a dangerous mix with drugs as potent as GLP-1s.Learn more at Drugwatch.com.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
Buchladen: Tipps für Weihnachten
20 Dec 2025
eat.READ.sleep. Bücher für dich
BOJ alza 25pb decennale sopra 2%, Oracle vola con accordo Tik Tok, 90 mld eurobond per Ucraina | Morning Finance
19 Dec 2025
Black Box - La scatola nera della finanza
365. The BEST advice for managing ADHD in your 20s ft. Chris Wang
19 Dec 2025
The Psychology of your 20s
LVST 19 de diciembre de 2025
19 Dec 2025
La Venganza Será Terrible (oficial)
Cuando la Ciencia Ficción Explicó el Mundo que Hoy Vivimos
19 Dec 2025
El Podcast de Marc Vidal